
Abivax SA (ABVX) Stock Forecast & Price Target
Abivax SA (ABVX) Analyst Ratings
Bulls say
Abivax is a biotechnology company with promising prospects in the development of a potential treatment for ulcerative colitis, obefazimod. While the company has potential for success in trials and collaborations in drug development, they also face challenges such as competition and potential safety concerns. With a primary strategic plan focused on M&A, the company's success may depend on their ability to overcome these risks and effectively market their drug. Analysts and industry experts are optimistic about the potential for growth in the IBD treatment market, providing a positive outlook for Abivax's stock.
Bears say
Abivax is a company with potential for upside if acquired, but also faces limitations with their drug obefazimod and potential competition in the growing market for IBD treatments. Additionally, their stock may suffer if acquisition fails and they may need additional financing.
This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.
Abivax SA (ABVX) Analyst Forecast & Price Prediction
Start investing in Abivax SA (ABVX)
Order type
Buy in
Order amount
Est. shares
0 shares